Humana Inc vs Tapestry, Inc. — how do they compare? Humana Inc trades at $447.4 (market cap $46.49B), while Tapestry, Inc. trades at $116.99 (market cap $23.09B). The key difference: Humana Inc is far larger — about 2× Tapestry, Inc.'s market cap, and Tapestry, Inc. pays the higher dividend (1.6%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Tapestry, Inc. for 70 Days on average.
| HUM | TPR | |
|---|---|---|
Market Cap | $46.49B | $23.09B |
Volume | 2,567,704 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $164.78 |
52-Week Low | $163.67 | $98.81 |
Typical Hold Time | 53 Days | 70 Days |
Enterprise Value | $53.84B | $25.89B |
Dividend Yield | 0.91% | 1.6% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
TPR trades at $113.39, down 2.86% today, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 19.09% net income margin and 197.14% ROE, but net income fell sharply in 2025. Recent earnings beats and a $0.46 dividend highlight operational strength, while cash flow volatility and high debt-to-asset ratios pose concerns. Analyst consensus is strongly bullish with a $174.64 price target.
Outlook remains positive driven by international growth and margin expansion targets, but risks include execution challenges at Kate Spade, tariff pressures, and volatile cash flows. The stock offers value with a reasonable P/E of 15.6, though current price weakness near support at $113 may present a buying opportunity for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →